Sclerosol Intrapleural Aerosol：治疗恶性胸腔积液; Bryan Corporation生产; 1998年1月批准上市
【通用名称】SCLEROSOL
【剂　　型】AEROSOL, METERED; INTRAPLEURAL
【规　　格】400MG/SPRAY
【活性成份】TALC
Sclerosol Intrapleural Aerosol
Company: Bryan Corporation
Approval Status: Approved January 1998
Treatment for: malignant pleural effusions
Areas: Cancer & Oncology; Respiratory
Adult Dosing & Uses
Dosing Forms & Strengths
intrapleural aerosol
4g/25g propellant, delivers 400mg/second
sclerosing powder
5g/100mL bottle
Malignant Pleural Effusion
Indicated as a sclerosing agent to decrease malignant pleural effusion recurrence in symptomatic patients
Administered intrapleurally via chest tube after adequate drainage of the effusion
Sclerosol: 4-8 g (1-2 canisters); deliver by manually pressing actuator button; distal end of the delivery tube should be pointed in several different directions, while short bursts are administered to distribute talc powder equally and extensively on all visceral and parietal pleural surfaces
Sterile Talc Powder: 5 g dissolved in 50-100 mL 0.9% NaCl
General Information
Sclerosol Intrapleural Aerosol has been approved for the prevention of recurrence of malignant pleural effusions in symptomatic patients. Symptoms include chest pain, dyspnea, and coughing. It is to be administered by aerosol during thracoscopy or open thoracotomy.
---------------------------------------------------------------
附件:
20127118420728.PDF